Atlas Trials

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Clinical trial NCT00674791 · COMPLETED

Trial details

NCT number
NCT00674791
Sponsor
Duke University
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2007-06-01
Primary completion
2010-01-01
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.